Autres langues Eris Lifesciences Limited Bombay S.E.

Actions

540596

INE406M01024

Marché Fermé - Bombay S.E. Autres places de cotation 12:00:53 01/07/2024			Varia. 5j.	Varia. 1 janv.
1 050 ^INR	+2,51%		+0,99%	+15,34%

12/06	Eris Lifesciences achève l'acquisition d'une participation de 19 % dans Swiss Parenterals	MT
11/06	Eris Lifesciences Limited (NSEI:ERIS) a finalisé l'acquisition d'une participation supplémentaire de 19% dans Swiss Parenterals Limited auprès d'Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah et Rajendra Rambhai Patel.	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Eris Lifesciences Completes Acquisition of 19% Stake in Swiss Parenterals	12/06
Eris Lifesciences Limited completed the acquisition of additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel.	11/06
Eris Lifesciences Posts Gains in Fiscal Q4 Consolidated Net Profit	22/05
Eris Lifesciences Gets Board Nod to Raise Up to INR12.50 Billion Via Bond Sale	21/05
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03/04
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15/03
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14/03
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14/03
Eris Lifesciences Limited agreed to acquire additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel for INR 2.4 billion.	14/03
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.	14/03
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	16/02
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	15/02
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	13/02
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.	13/02
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	08/02
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	10/11
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations, India Business Units	09/11
Indian shares set to open higher tracking Asian peers	09/11
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024	08/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Eris Lifesciences Limited Bombay S.E.

Actions

540596

INE406M01024

Autres langues

Filtres